Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer's disease patients of Northern Han Chinese descent

Current Alzheimer Research

Volumn 10, Issue 1, 2013, Pages 57-62

  Bai, Lin ^a   Song, Ning ^a   Yu, Jintai ^a   Tan, Lan ^a   Shen, Yong ^b   Xie, Junxia ^a   Jiang, Hong ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b ROSKAMP INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Amyloid beta peptides; Soluble tumor necrosis factor receptor; Tumor necrosis factor converting enzyme

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ADAM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAUCASIAN; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; ASIAN; BLOOD; CASE CONTROL STUDY; ETHNOLOGY; FEMALE; MALE; MENTAL HEALTH; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOASSAY; LINEAR MODELS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879504934     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720513804871417     Document Type: Article

References (43)

1. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698-712 (2011).
2. Zhang ZX, Zahner GE, Roman GC, Liu J, Hong Z, Qu QM et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol 62: 447-453 (2005).
3. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 115: 1121-1129 (2005).
4. Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT. Role of the APP non-amyloidogenic signaling pathway and targeting alpha- secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 14: 2848-2864 (2007).
5. Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT. Novel drug targets based on metallobiology of Alzheimer's disease. Expert Opin Ther Targets 14: 1177-1197 (2010).
6. Bandyopadhyay S, Hartley DM, Cahill CM, Lahiri DK, Chattopadhyay N, Rogers JT. Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. J Neurosci Res 84: 106-118 (2006).
7. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35: 419-432 (2002).
8. Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA, Martin Watterson D. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol 82: 277-296 (2007).
9. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 5: 2 (2008).
10. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 10: 45-65 (2003).
11. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275: 14608-14614 (2000).
12. Aderka D, Engelmann H, Shemer-Avni Y, Hornik V, Galil A, Sarov B et al. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 11: 157-159 (1992).
13. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54: 1-8 (1995).
14. Lantz M, Malik S, Slevin ML, Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2: 402-406 (1990).
15. Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol 10: 654-659 (1998).
16. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765-27767 (1998).
17. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 96: 3922-3927 (1999).
18. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 113 (Pt 11): 1857-1870 (2000).
19. Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R et al. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol Neurodegener 6: 69 (2011).
20. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 31: 1877-1884 (2010).
21. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 12: 215-227 (1998).
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984).
23. Zimina EP, Fritsch A, Schermer B, Bakulina AY, Bashkurov M, Benzing T et al. Extracellular phosphorylation of collagen XVII by ecto-casein kinase 2 inhibits ectodomain shedding. J Biol Chem 282: 22737-22746 (2007).
24. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 113: 1685-1695 (2006).
25. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 83: 470S-474S (2006).
26. Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 24: 157-165 (2006).
27. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 27: 741-749 (2003).
28. Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26: 349-354 (2005).
29. Reale M, Brenner T, Greig NH, Inestrosa N, Paleacu D. Neuroinflammation, AD, Dementia. Int J Alzheimers Dis (2010).
30. Stozicka Z, Zilka N, Novak P, Kovacech B, Bugos O, Novak M. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease. J Neuroinflammation 7: 64 (2010).
31. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 25: 8240-8249 (2005).
32. Dembic Z, Loetscher H, Gubler U, Pan YC, Lahm HW, Gentz R et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 2: 231-237 (1990).
33. Tartaglia LA, Goeddel DV. Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. J Biol Chem 267: 4304-4307 (1992).
34. He Y, Liu J, Grossman D, Durrant D, Sweatman T, Lothstein L et al. Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J Cell Biochem 101: 1210-1221 (2007).
35. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74: 845-853 (1993).
36. Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J Immunol 181: 3877-3886 (2008).
37. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE et al. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170: 680-692 (2007).
38. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C et al. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178: 829-841 (2007).
39. Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 279: 49523-49532 (2004).
40. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733 (1997).
41. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC et al. An essential role for ectodomain shedding in mammalian development. Science 282: 1281-1284 (1998).
42. Canault M, Leroyer AS, Peiretti F, Leseche G, Tedgui A, Bonardo B et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 171: 1713-1723 (2007).
43. Wang J, Li Z, Al-Lamki R, Zuo N, Bradley JR, Wang L. The role of tumor necrosis factor-alpha converting enzyme in renal transplant rejection. Am J Nephrol 32: 362-368 (2010).